The obesity drug landscape
CagriSema did not arrive in a vacuum. It competes in the most active area of drug development in a generation, against…
Where CagriSema sits in a crowded field
CagriSema did not arrive in a vacuum. It competes in the most active area of drug development in a generation, against approved heavyweights (semaglutide, tirzepatide) and other investigational multi-hormone drugs (retatrutide, survodutide, eloralintide).
This unit places CagriSema honestly on that map: competitive on weight loss, distinctive in mechanism, but behind on the cardiovascular, liver, and durability evidence its rivals have accumulated.
Key terms
Weight loss, side by side
The first question everyone asks is "how much weight?" Placed against its rivals, CagriSema is competitive but not dominant. It clearly beats semaglutide alone, which reached 14.9% at 68 weeks in STEP 1, but the direct comparison at full doses, REDEFINE 4, put it slightly behind tirzepatide. A second head-to-head, REIMAGINE 5, reported in a sponsor topline of 21 September 2026, compared the lowest doses of each drug in type 2 diabetes: CagriSema 1.0 mg/1.0 mg reached 12.4% against 9.1% on tirzepatide 5 mg at week 60, on the efficacy estimand. Figures circulating for other investigational drugs, such as retatrutide, come from trials this course has not verified, so they are reported, not verified, and no honest ranking can be built from them.
A crucial caveat sits under this chart: the first two bars come from different trials, timepoints, and populations, so they are suggestive, not a fair head-to-head. The exception is tirzepatide. In REDEFINE 4 (open-label, n=809 randomised, 84 weeks) CagriSema lost 23.0% against tirzepatide 15 mg at 25.5% on the efficacy estimand, and 20.2% against 23.6% on the treatment-regimen estimand, and the trial did not achieve its primary endpoint of demonstrating non-inferiority. Those figures come from a sponsor announcement rather than a peer-reviewed paper, and the registry carries no posted results. The honest read is that CagriSema is in the top tier of weight-loss efficacy, and that claims it is "the strongest" now run against a direct trial result.
Except for tirzepatide, these bars are from separate trials, not head-to-heads. In the full-dose direct comparison, REDEFINE 4, CagriSema came in below tirzepatide; in the lower-dose comparison, REIMAGINE 5, it came in above. The doses decide the answer.